Wadhane Jitendra 4

What Happened

• Jitendra Wadhane, Pyxis Oncology’s Principal Financial & Accounting Officer, was granted equity awards on 2026-03-24 totaling 372,096 shares: 109,461 restricted stock units (RSUs) and a derivative award covering 262,635 shares (an option/other equity-based award). Both awards show an acquisition price of $0.00, so there was no cash paid or received at grant.

Key Details

• Transaction date: 2026-03-24; SEC filing date: 2026-03-25 (timely).
• Price: $0.00 per share for both awards; reported aggregate acquisition value = $0.
• Vesting: RSUs vest 25% on March 31, 2026, then in 36 substantially equal monthly installments thereafter (footnote F1). The derivative/option award vests over four years with 25% vesting on the first anniversary of March 24, 2026 and the remainder in 36 equal monthly installments (footnote F2).
• Shares owned after transaction: not specified in the disclosed excerpt of the filing.
• Transaction code: A = Award/Grant; the 262,635-share item is a derivative award (option-like) — this is a grant, not an exercise or sale.
• No 10b5-1 plan, tax-withholding, cashless exercise, or other special conditions were disclosed in the provided filing excerpt.

Context

• These are standard compensation grants (RSUs and a time-based derivative/option award) that vest over time and do not indicate an immediate purchase or sale of stock. Because no shares were sold, there is no immediate market impact or proceeds to the insider.